Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • Malaria & vaccines
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • Research & development
    • Our research and development strategy
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Evaluation technologies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • The decision-making framework tool for malaria vaccines
      • Decision-making framework
        • Economic analysis
        • Public health impact analysis
        • Sociocultural research
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Malaria & vaccines
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • Research & development
    • Our research and development strategy
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Evaluation technologies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • The decision-making framework tool for malaria vaccines
      • Decision-making framework
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Home
  • Home

PATH applauds WHO recommendation for broader use of first malaria vaccine in sub-Saharan Africa

Vaccine shown to be cost-effective and trusted by caregivers and health care workers

PATH welcomes landmark financing agreement for GSK's malaria vaccine

PATH congratulates Gavi, GSK, and MedAccess for joining forces to help ensure an ongoing supply of the first malaria vaccine, RTS,S/AS01E. 

PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi

Funding from Open Philanthropy Foundation will expand access to RTS,S/AS01 in pilot areas of Ghana, Kenya, and Malawi...

PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S

Together with partners and other stakeholders, PATH is working to help ensure sufficient malaria vaccine supply to meet potential demand.

Home

  • Malaria parasite life cycle

    Many factors make malaria vaccine development challenging.
    Explore
  • Vaccine development

    Vaccinologists pursue different approaches to developing malaria vaccines.
    Explore
  • RTS,S

    RTS,S is the first malaria vaccine recommended for broad use by WHO
    Explore

Latest

RTS,S/AS01 malaria vaccine being drawn up by a healthcare worker in western Kenya. PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi
Press release
19 Apr 2022
PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S
Press release
2 Dec 2021
PATH applauds WHO recommendation for broader use of first malaria vaccine
Press release
6 Oct 2021
Frequently Asked Questions (FAQs): RTS,S/AS01 for seasonal use
Fact sheet
25 Aug 2021
PATH welcomes remarkable results from clinical trial combining RTS,S/AS01 malaria vaccine with Seasonal Malaria Chemoprevention
Press release
25 Aug 2021
PATH welcomes landmark financing agreement for GSK’s malaria vaccine
Press release
4 Aug 2021
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
Press release
27 Jan 2021
Frequently Asked Questions (FAQs): Product Transfer for the RTS,S/AS01 Malaria Vaccine
Fact sheet
27 Jan 2021
Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine
Press release
22 Jul 2020
PATH receives new five-year contract from USAID for malaria vaccine research and development
Press release
7 Jul 2020
A child sits with his mother Two families reflect on their malaria vaccine journey
Feature
23 Apr 2020
PATH continues exciting partnership with the GHIT Fund to develop a next-generation malaria vaccine
Press release
3 Apr 2020
  • Need for vaccines

    Vaccines can help to close the gap left by other malaria control interventions.
  • Malaria vaccine roadmap

    The roadmap outlines a path for accelerating the development of malaria vaccines.
  • RTS,S

    RTS,S is the first malaria vaccine recommended for broad use by WHO
  • Next-generation vaccines

    The next generation of malaria vaccines would aim to reduce transmission of the parasite.

Twitter @MalariaVaccine

President Kenyatta: We Need Vaccines and Investment to Tip the Scales Against Malaria https://t.co/nLrwLT7p1o
28 Jun 2022
RT @TheLancetInfDis: New Research: Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and del… https://t.co/F532o3Z7wE
27 Jun 2022
RT @PATHtweets: How is the COVID-19 pandemic changing the vaccine landscape? The inaugural issue of @VaccineInsights, guest edited… https://t.co/zbzkCa148m
23 Jun 2022
RT @MedsforMalaria: On #AfricanChildDay, Abena Poku-Awuku and André-Marie Tchouatieu reflect on 10 years of seasonal malaria chemopreve… https://t.co/OkVfHEenx7
16 Jun 2022
RT @gavi: At a time when #COVID19 vaccines were developed and authorised in less than one year, the delay for malaria raises… https://t.co/9wB3xnVSuS
13 Jun 2022
RT @ADP_health: The world’s first malaria vaccine and beyond - @PATHtweets’s Ashley Birkett answers questions on the RTS,S #malaria… https://t.co/hN5zAxBGlY
6 Jun 2022
RT @PATHtweets: Undark speaks with PATH’s Global Head of Malaria Vaccines, Ashley Birkett, plus partners about the first-generation… https://t.co/WhUSxdksvS
1 Jun 2022
RT @PATHMalaria: We're #hiring! Our PATH Malaria team has exciting new roles open for a project focused on the delivery of facility… https://t.co/42nQgOpsDS
31 May 2022
RT @undarkmag: By the time a vaccine for malaria was approved, vaccines for Covid-19 had already been developed and authorized aro… https://t.co/G4Qyy7hW1Y
25 May 2022
RT @WHO: 🗝️ Highlight #2 In 2021, WHO recommended the use of the 🌐’s first & only #malaria vaccine among children in sub-Sa… https://t.co/R35KTjGPzv
24 May 2022
Malawi's village volunteers go door-to-door with vaccine messages https://t.co/GFigKhXeg6 @pathtweets
11 May 2022
RT @PATHtweets: The world’s first malaria vaccine is here, but what’s next in malaria vaccine development? @PATHtweets’ Dr. Ashley… https://t.co/F0bu8Y4Bmz
9 May 2022

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2022 PATH
Website by Manta Ray Media